AVN to Receive $5 Million Milestone
AVANIR Pharmaceuticals (AMEX: AVN) announced that a Phase I study has been initiated in partnership with AstraZeneca UK Limited (AstraZeneca) to evaluate the human safety of AZD2479, a compound under development as a reverse cholesterol transport enhancer. The allowance of the investigational new drug application (IND) by the U.S. Food and Drug Administration (FDA) triggers a $5 million milestone payment from AstraZeneca to AVANIR, the first designated milestone under the terms of the research collaboration and license agreement entered into in July 2005.
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- Mylan (MYL) Unit Launches Generic Viramune Tabs
- Pluristem (PSTI) CEO Aberman Sends Letter to Shareholders;
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
